Underneath the impressive market rally is a trend that doesn't seem quite right, according to J.P. Morgan.Marketsread more
Tesla is working on new battery cell designs, and a way to make their own cells, with R&D teams in a lab near its car plant in Fremont, California.Technologyread more
The Federal Reserve and the market are miles apart on interest rate expectations, and the disparity could cost the stock market a 7%-10% drop, economists say.Economyread more
JP Morgan's Jamie Dimon says student lending "is a disgrace and it's hurting America."Economyread more
Bitcoin topped the $13,000 level Wednesday, rallying to its highest price since January 2018.Bitcoinread more
Online home goods retailer Wayfair sold roughly 1,600 mattresses and 100 bunk beds to Baptist Child and Family Services, a nonprofit that works as a federal contractor...Retailread more
The Senate will try to reconcile its emergency border aid plan with one passed by Nancy Pelosi and House Democrats.Politicsread more
During the foreclosure crisis, investors transformed the single-family home rental market into a formally managed asset class. Now they want new homes.Real Estateread more
Lenders including J.P. Morgan Chase and Bank of America are widely expected to increase dividends this week.Financeread more
The president raised $6 million alone at a fundraiser he attended at the Trump International Hotel on Tuesday in Washington.Politicsread more
The first debates will give most of the contenders their biggest platform yet to present themselves to the American people.Politicsread more
Drugmakers have been under scrutiny since Mylan's EpiPen price hike, but government involvement in controlling costs is not necessarily the answer, Wells Fargo Securities analyst David Maris said Thursday.
"I don't think that having government run that process is really the right way, because it's a Trojan horse for price controls. Once they start controlling a little bit of price, then the temptation is to control all of price, and if you do that, you really get fewer drugs invented," he said in an interview with CNBC's "Power Lunch " from the Wells Fargo Healthcare Conference in Boston.
Instead, Maris thinks the pharmaceutical industry will likely follow Allergan's example of policing its prices.
The Botox-maker has said it will raise prices no more than once a year and keep the hikes to no more than low-to-mid-single-digit percentages.
Maris called the move brilliant, and said it reflects the current corporate culture.
"Everyone understands that drug companies should make a little bit more each year; that their costs go up. Their people have to get paid more. Science costs more to do. But if we could limit maybe the outliers," he said.
Mylan has come under fire for boosting the price of its anti-allergy injection device to more than $600 — up from about $100 in 2008. The company has since said it will launch the first generic version of the drug at half the price.